A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Urothelial Carcinoma
Oral Drug Administration
Open Label

Interventions

DRUG: FX-909
DRUG: Pembrolizumab (KEYTRUDA ®)
DRUG: KEYTRUDA ®( Pembrolizumab)

Sponsor

Flare Therapeutics Inc.

Collaborators

[object Object]